|
|
|
|
|
Palivizumab
drug data and news
Palivizumab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Palivizumab | ||
| Brand Names/Synonyms | Synagis; anti-RSV; Synagis (MedImmune Inc) | ||
| Indication | For treatment of respiratory diseases casued by respiratory syncytial virus | ||
| Sponsored links | Description | humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF) | |
| Pharmacology | Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients. | ||
| Mechanism Of Action | Binds to the outer coat or Fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors. | ||
| Palivizumab News (When available) |
MedImmune Awarded $170 Million Five-Year Contract From US Health ... May 10, 2006 MedImmune Reports Financial Results for First Quarter 2006 Apr 20, 2006 | ||
| Dosage Forms | POWDER FOR SOLUTION | ||
| Drug_Category | Antiviral Agents; monoclonal antibodies (08:18.24) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Not Available | ||
| Chemical IUPAC Name | Humanized anti-RSV antibody | ||
| Chemical Formula | Not Available | ||
| Molecular Weight | Not Available | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Most likely removed by opsonization via the reticuloendothelial system. | ||
| Half Life | 18 days (in adults) | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Palivizumab.html http://www.rxlist.com/cgi/generic2/palivizumab.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00097 | ||
| CAS Registry Number | 60574-4111-01 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA450764 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2245889 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |